OncoMatch/Clinical Trials/NCT05961410
Eltrombopag for Peripheral Blood Stem Cell Harvest
Is NCT05961410 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Eltrombopag olamine for lymphoma.
Treatment: Eltrombopag olamine — The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are: * Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest. * Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization. Participants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any systemic therapy
after at least 2 cycles of treatment
Cannot have received: eltrombopag (eltrombopag)
Current administration of eltrombopag
Lab requirements
Blood counts
Steady state platelet count ≤ 1000k/μL
Liver function
Baseline serum aspartate aminotransferase (AST), alanine aminotransferase(ALT) or total bilirubin ≤ 3 fold of upper limit of normal
Steady state platelet count > 1000k/μL [excluded]; Baseline serum aspartate aminotransferase (AST), alanine aminotransferase(ALT) or total bilirubin > 3 fold of upper limit of normal [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify